AU2023216271A1 - Methods of treatment using t-type calcium channel modulators - Google Patents

Methods of treatment using t-type calcium channel modulators Download PDF

Info

Publication number
AU2023216271A1
AU2023216271A1 AU2023216271A AU2023216271A AU2023216271A1 AU 2023216271 A1 AU2023216271 A1 AU 2023216271A1 AU 2023216271 A AU2023216271 A AU 2023216271A AU 2023216271 A AU2023216271 A AU 2023216271A AU 2023216271 A1 AU2023216271 A1 AU 2023216271A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
formula
compound
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023216271A
Other languages
English (en)
Inventor
Bernard RAVINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of AU2023216271A1 publication Critical patent/AU2023216271A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023216271A 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators Pending AU2023216271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
US63/306,340 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
AU2023216271A1 true AU2023216271A1 (en) 2024-08-15

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023216271A Pending AU2023216271A1 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Country Status (10)

Country Link
US (1) US20250170114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4472633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025505578A (cg-RX-API-DMAC10.html)
KR (1) KR20240144291A (cg-RX-API-DMAC10.html)
CN (1) CN118785905A (cg-RX-API-DMAC10.html)
AU (1) AU2023216271A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243616A1 (cg-RX-API-DMAC10.html)
IL (1) IL314576A (cg-RX-API-DMAC10.html)
MX (1) MX2024009559A (cg-RX-API-DMAC10.html)
WO (1) WO2023150703A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド 4−フルオロ−ピペリジンt型カルシウムチャネルアンタゴニスト
RU2746188C2 (ru) * 2015-11-12 2021-04-08 Афаски, Инк. Ингибиторы ионного канала, фармацевтические составы и применение
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
WO2021007487A1 (en) * 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CN115776894A (zh) * 2020-04-29 2023-03-10 普拉西斯精密医药公司 T型钙通道调节剂的使用方法
JP7841757B2 (ja) * 2020-11-09 2026-04-07 プラクシス プレシジョン メディシンズ, インコーポレイテッド T型カルシウムチャネル調節因子及びその使用方法
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
EP4472633A2 (en) 2024-12-11
WO2023150703A3 (en) 2023-09-14
JP2025505578A (ja) 2025-02-28
US20250170114A1 (en) 2025-05-29
MX2024009559A (es) 2024-09-23
CN118785905A (zh) 2024-10-15
WO2023150703A2 (en) 2023-08-10
EP4472633A4 (en) 2026-01-14
IL314576A (en) 2024-09-01
CA3243616A1 (en) 2023-08-10
KR20240144291A (ko) 2024-10-02

Similar Documents

Publication Publication Date Title
US12077502B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
JP2010539118A (ja) 蝸牛性耳鳴の治療用1−アミノ−アルキルシクロヘキサン誘導体
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
MX2012001814A (es) Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso.
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
US20250170114A1 (en) Methods of treatment using t-type calcium channel modulators
WO2025188619A1 (en) Methods of treating parkinson's disease with t-type calcium channel modulators
WO2026085384A1 (en) Methods of treating essential tremor
RU2438658C2 (ru) Производные 1-аминоалкилциклогексана для лечения кохлеарного тиннитуса
WO2015166917A1 (ja) 耳鳴患者の治療用の薬剤